Monoclonal antibody chemotherapy involves the injection of antibodies that locate and disrupt receptors associated with cancer, such as ErbB-2-targeting trastuzumab and EpCAM/CD326-targeting adecatumumab [222,223]. Here, ERBB2 is linked to cancer.